A bipartisan pair of federal lawmakers are rebranding and relaunching a congressional caucus to promote research into and awareness around psychedelic-assisted therapy, hoping to shine a light on the practice’s potential to treat a variety of mental health conditions.
The renamed Congressional Psychedelics Advancing Therapies (PATH) Caucus, which was described exclusively to Marijuana Moment ahead of its formal announcement in a press release on Thursday morning, aims to inform fellow lawmakers of the growing evidence from leading research institutions that therapy involving substances like psilocybin and MDMA can help effectively treat PTSD, depression and substance use disorder.
The group’s founders, Reps. Lou Correa (D-CA) and Jack Bergman (R-MI), say the caucus will also push for more federal research funding and convene bipartisan thought leaders to brief Congress on scientific evidence around psychedelics.
In a phone interview with Marijuana Moment a day before the announcement, Correa said the group’s goal is “to make sure that folks in Congress are aware of what’s going on in this area of evidence-based psychedelic science.”
“The issue before us as a society is mental health: drug addiction, alcoholism, PTSD, veterans afflicted by those invisible wounds,” said the Orange County Democrat. “We owe it to our
Read full article on Marijuana Moment
